Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/3/?d=1Neue Studien: Europe PMCdeLower CALLY index values are associated with higher disease activity in psoriatic arthritis: a retrospective cohort study.https://www.psoriasis-news.de/articles.html/1_articles/lower-cally-index-values-are-associated-with-higher-disease-activity-in-psoriatic-arthritis-a-retrospective-cohort-study-r653/Weiterlesen

]]>653Fri, 03 Jul 2026 07:03:51 +0000Molecular dissection of CD28-associated cytokine signaling in early psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/molecular-dissection-of-cd28-associated-cytokine-signaling-in-early-psoriasis-r652/BackgroundPsoriasis is a chronic immune-mediated skin disorder characterized by excessive keratinocyte proliferation and abnormal T-cell activation. Cluster of Differentiation 28 (CD28), a costimulatory protein, plays a crucial role in psoriasis pathophysiology by enhancing T-cell activation and promoting cytokine release.

Methods

A case-control study was involving 168 newly diagnosed psoriasis patients and 159 healthy control individuals (HC), Genotyping of rs1879877 in promoter of CD28 gene was performed using the tetra-primer amplification refractory mutation system-polymerase chain reaction (T-ARMS-PCR), and serum levels of soluble CD28 (sCD28) and selected cytokines (Interleukin (IL), IL-38, IL-39 and Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)) were measured using sandwich enzyme-linked immunosorbent assay (ELISA).

Results

The heterozygous GT genotype was predominant among psoriasis patients and was significantly associated with elevated serum sCD28 levels compared to controls, who predominantly carried the wild type GG genotype. Elevated sCD28 levels were linked to increased T-cell activation, contributing to immune dysregulation and disease severity. This was evidenced by increased production of pro-inflammatory cytokines, including IL-39 and GM-CSF, with a concurrent decrease in the anti-inflammatory cytokine IL-38.

Conclusion

Serum sCD28 levels were significantly elevated in psoriasis patients. The CD28 gene variant rs1879877 (-1198 G/T) appears to be associated with psoriasis pathogenesis, potentially due to increased transcriptional activity that elevates sCD28 expression, thereby influencing T-cell activation and immune modulation.

Weiterlesen

]]>652Fri, 03 Jul 2026 07:03:51 +0000Biologic therapies in pediatric psoriasis: A single-center experience.https://www.psoriasis-news.de/articles.html/1_articles/biologic-therapies-in-pediatric-psoriasis-a-single-center-experience-r651/Weiterlesen

]]>651Fri, 03 Jul 2026 07:03:51 +0000Clinical Characteristics, Healthcare Resource Utilization, and Costs of Patients with Generalized Pustular Psoriasis in Taiwan: A National Claims Database Study.https://www.psoriasis-news.de/articles.html/1_articles/clinical-characteristics-healthcare-resource-utilization-and-costs-of-patients-with-generalized-pustular-psoriasis-in-taiwan-a-national-claims-database-study-r650/BackgroundGeneralized pustular psoriasis (GPP) is a rare and severe inflammatory disease characterized by widespread pustular eruptions and systemic inflammation.

Objective

To evaluate the clinical characteristics and disease burden of patients with GPP in Taiwan using a national claims database.

Methods

Patients with GPP and no prior diagnosis of psoriasis vulgaris (PV) who experienced an incident flare between January 1, 2017, and September 30, 2020, were identified from Taiwan's National Health Insurance Database. Clinical characteristics, comorbidities, and treatment patterns were described. Recurrent flare frequency, healthcare resource utilization (HCRU) and costs were compared with those of a propensity score-matched PV cohort at a ratio of up to 1:4. Outpatient-managed flares were classified as moderate, whereas hospitalized flares were classified as severe.

Results

A total of 245 patients with GPP were included (mean age 51.3 years; 49.8% male). During follow-up, 1,156 moderate-to-severe flares were identified. Compared with matched patients with PV, patients with GPP had a higher recurrent flare rate (rate ratio 1.14; 95% CI 1.06-1.23). Patients with GPP also had greater HCRU, including more outpatient visits (incidence rate ratio [IRR] 1.03 [95% CI 1.01-1.05]), emergency room visits (IRR 1.33, 95% CI 1.19-1.49), and hospital admissions (IRR 1.69 [1.50-1.91]). Median monthly healthcare costs were approximately twice as high among patients with GPP as among matched patients with PV.

Conclusion

Patients with GPP experienced recurrent flares, greater healthcare utilization, and higher healthcare costs than matched patients with PV, underscoring the substantial real-world clinical and economic burden of GPP.

Weiterlesen

]]>650Fri, 03 Jul 2026 07:03:51 +0000Real-World Effectiveness of Tildrakizumab in Japanese Patients With Psoriasis: Analyses Stratified by Prior Systemic Therapy, Maintenance of Early Responses, and Achievement of Delayed Responses.https://www.psoriasis-news.de/articles.html/1_articles/real-world-effectiveness-of-tildrakizumab-in-japanese-patients-with-psoriasis-analyses-stratified-by-prior-systemic-therapy-maintenance-of-early-responses-and-achievement-of-delayed-responses-r649/Weiterlesen

]]>649Fri, 03 Jul 2026 07:03:51 +0000Two-dimensional GeTe nanosheets for psoriasis through modulation of macrophage activation and psoriatic inflammation.https://www.psoriasis-news.de/articles.html/1_articles/two-dimensional-gete-nanosheets-for-psoriasis-through-modulation-of-macrophage-activation-and-psoriatic-inflammation-r648/In vivo, the oral administration of GeTe-NSs in an IMQ-induced psoriasis mouse model resulted in significant improvements in clinical scores, epidermal thickening, and the proportions of M1/M2 macrophages in spleen and skin lesions. Taken together, these findings suggest that GeTe-NSs could be a promising nanomaterial for treating inflammatory diseases, including psoriasis.

Weiterlesen

]]>648Fri, 03 Jul 2026 07:03:51 +0000<![CDATA[Extracellular vesicles as biomarkers for psoriatic arthritis: a systematic review & meta-analysis]]>https://www.psoriasis-news.de/articles.html/1_articles/extracellular-vesicles-as-biomarkers-for-psoriatic-arthritis-a-systematic-review-meta-analysis-r647/Background Psoriatic arthritis (PsA) is an inflammatory condition involving joints, tendon-bone entheses and synovium that can develop in individuals with psoriasis. Early, accurate clinical diagnosis remains difficult. Extracellular vesicles (EVs) carry proteins and miRNAs that

Methods

PubMed and Embase were searched from inception through May 21st, 2026, and human studies examining EV-associated protein or miRNA biomarkers in PsA and related psoriatic or inflammatory diseases were included, with risk of bias assessed using a modified Newcastle-Ottawa Scale and diagnostic accuracy summarized using HSROC/BRMA models when data were sufficient.

Results

Seven studies met the inclusion criteria, including 119 individuals with PsA (weighted mean age: 49.8 years; 43.7% female), 205 individuals with non-PsA psoriasis (weighted mean age: 46.4 years; female %: NA), 55 controls (weighted mean age: 44.5 years; 38.2% female), and 50 individuals with other inflammatory joint disorders (weighted mean age: 58.0 years; 58.0% female). EV-associated protein markers demonstrated heterogeneous findings related to immune, vascular, inflammatory, and osteoimmunological signaling. Only 4.2% (4/95) of miRNAs were consistently identified across studies comparing PsA with non-PsA psoriasis, with lower overlap (1.5%, 1/67) in studies comparing PsA with controls. ROC meta-analysis suggested preliminary diagnostic potential, particularly for distinguishing PsA from non-PsA psoriasis, although evidence was constrained by small study numbers.

Conclusions

EV-associated proteins and miRNAs are potential biomarker candidates for PsA, reflecting inflammatory, vascular, and osteoimmunological processes underlying disease pathophysiology. However, current evidence remains preliminary and limited by small cohorts, methodological heterogeneity, and inconsistent reporting across studies.

Weiterlesen

]]>647Mon, 29 Jun 2026 08:21:12 +0000A Serum N-Glycan Ratio Associated With Disease Severity and Treatment Response in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/a-serum-n-glycan-ratio-associated-with-disease-severity-and-treatment-response-in-psoriasis-r646/Weiterlesen

]]>646Mon, 29 Jun 2026 08:21:12 +0000Exploring the Gut Microbiome's Association in Psoriasis and Psoriatic Arthritis: A Scoping Review.https://www.psoriasis-news.de/articles.html/1_articles/exploring-the-gut-microbiomes-association-in-psoriasis-and-psoriatic-arthritis-a-scoping-review-r645/IntroductionPsoriasis (PsO) and psoriatic arthritis (PsA) are chronic inflammatory conditions treated with primarily immune-modulating medication. However, interest is growing in gut microbiome therapies. Studies have reported altered gut microbiota in PsO/PsA and explored probiotics and fecal microbiota transplantation (FMT) as potential therapies. This review synthesizes global studies on the microbiome's associations in PsO/PsA.

Methods

We conducted a scoping literature review to understand the association between gut microbiota in PsO and PsA patients. Pubmed was used to identify 4,126 published manuscripts between 2015-2025. Thirty studies were included, encompassing 749,275 participants, with balanced gender representation and ages ranging from 18 to 76 years. These studies included 21 case-control studies, 1 case-series, 2 genome-wide analyses, 5 clinical trials, and 1 retrospective review.

Results

Eighteen studies reported significant gut microbiome differences in PsO/PsA vs healthy controls. Variation in the Firmicutes/Bacteroides (F/B) ratio was of interest, with one study suggesting a low F/B ratio and five studies suggesting an elevated F/B ratio in PsO. A higher F/B ratio was linked to increased acetate production. Acetate and propionate, key short-chain fatty acids (SCFAs), were associated with modulation of the IL-23/Th17 axis in psoriasis and activation of keratinocytes. The role of therapeutics targeting the gut microbiome was explored. Ustekinumab and tofacitinib altered gut microbiome composition. Probiotic and FMT interventions showed mixed outcomes. Six of eight probiotic studies reported increased SCFA producing species and/or reduced inflammatory markers. FMT improved immune markers in mice but had no significant benefit in human trials.

Conclusion

Alterations in the microbiome linked to inflammation and immune response, suggest the microbiome as a potential therapeutic target for PsO/PsA.

Weiterlesen

]]>645Mon, 29 Jun 2026 08:21:12 +0000A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain.https://www.psoriasis-news.de/articles.html/1_articles/a-cohort-study-of-obese-patients-with-moderate-to-severe-psoriasis-using-biological-medicines-in-catalonia-spain-r644/Weiterlesen

]]>644Mon, 29 Jun 2026 08:21:12 +0000<![CDATA[Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a <i>post hoc</i> analysis of a phase-III trial.]]>https://www.psoriasis-news.de/articles.html/1_articles/efficacy-of-vunakizumab-in-patients-with-moderate-to-severe-plaque-psoriasis-across-diverse-disease-features-a-ltigtpost-hocltigt-analysis-of-a-phase-iii-trial-r643/BackgroundThe efficacy of interleukin-17 inhibitors may be impacted by baseline psoriasis features.

Objective

This post hoc analysis aimed to explore the efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis stratified by diverse disease features.

Methods

This post hoc analysis used data from a phase III trial (NCT04839016); 690 patients with moderate-to-severe plaque psoriasis receiving vunakizumab (n = 461) or placebo (n = 229) were included.

Results

The proportions of patients achieving Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100, and static physician's global assessment (sPGA) 0/1 responses at week (W)12 were significantly higher in the vunakizumab group than in the placebo group, regardless of the duration of psoriasis, PASI score, body surface area (BSA) involvement, and sPGA score. Similarly, at W4 and W8, treatment response rates were higher in the vunakizumab group than in the placebo group, regardless of the above-mentioned features. The same trend was also found at W24. However, treatment responses at W52 were almost not different between patients continuously receiving vunakizumab and those switching from placebo to vunakizumab, regardless of disease duration and disease severity.

Conclusion

Vunakizumab shows satisfactory efficacy in patients with moderate-to-severe plaque psoriasis, regardless of psoriasis duration and severity.

Weiterlesen

]]>643Mon, 29 Jun 2026 08:21:12 +0000Psoriasis, Atopic Dermatitis, Acne, Inverse Psoriasis and Hidradenitis: A Case Report of Multiple Disease in a Same Young Patient.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-atopic-dermatitis-acne-inverse-psoriasis-and-hidradenitis-a-case-report-of-multiple-disease-in-a-same-young-patient-r642/Weiterlesen

]]>642Mon, 29 Jun 2026 08:21:12 +0000Frequency of complex-to-manage, difficult-to-manage and treatment-refractory psoriatic arthritis: applying the 2025 GRAPPA and EULAR definitions in a real-world longitudinal PsA cohort.https://www.psoriasis-news.de/articles.html/1_articles/frequency-of-complex-to-manage-difficult-to-manage-and-treatment-refractory-psoriatic-arthritis-applying-the-2025-grappa-and-eular-definitions-in-a-real-world-longitudinal-psa-cohort-r641/ObjectivesTo determine the frequency and baseline characteristic differences of complex-to-manage (C2M), difficult-to-manage (D2M) and treatment-refractory (TR) psoriatic arthritis (PsA) in a real-world longitudinal cohort, using the recently proposed 2025 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) definitions.

Methods

We analysed data from newly diagnosed, disease-modifying antirheumatic drug-naïve patients with PsA enrolled in the Dutch Southwest Early Psoriatic Arthritis cohort between 2013 and 2023. Patients were classified using the 2025 GRAPPA (C2M, TR) and EULAR (D2M, TR) PsA definitions. Frequencies were calculated for each definition. Time-to-event analyses using Kaplan-Meier methods assessed the timing of definition fulfilment and individual components. Longitudinal differences in patient-reported outcomes (PROs) were assessed using linear mixed-effects models.

Results

Among 885 newly diagnosed patients with PsA, 20% (179/885) fulfilled the GRAPPA-C2M definition, 4.2% (37/885) fulfilled the EULAR-D2M definition, 3.8% (34/885) met the EULAR-TR and 1.2% (11/885) fulfilled the GRAPPA-TR criteria definition during follow-up. Female sex, higher body mass index (BMI), longer symptom duration, presence of enthesitis and greater skin involvement differed with meeting definitions at baseline. Patients classified as GRAPPA-C2M, GRAPPA-TR, EULAR-D2M and EULAR-TR consistently reported worse long-term PROs (Health Assessment Questionnaire-Disability Index scores in C2M (β=0.17, 95% CI 0.10 to 0.24), GRAPPA-TR (β=0.37, 95% CI 0.22 to 0.51), EULAR-D2M (β=0.36, 95% CI 0.20 to 0.48) and EULAR-TR (β=0.40, 95% CI 0.25 to 0.55)).

Conclusions

Approximately 20% of patients with early PsA fulfilled the GRAPPA-C2M criteria, representing the earliest and broadest subgroup, while 4% met EULAR-D2M/EULAR-TR and 1.2% GRAPPA-TR definitions. These latter subgroups were more likely to be female, had higher BMI, greater skin involvement and enthesitis and experienced persistently worse PROs, underscoring the need for tailored management strategies.

Weiterlesen

]]>641Mon, 29 Jun 2026 08:21:12 +0000A Review of Male Genital Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/a-review-of-male-genital-psoriasis-r640/Weiterlesen

]]>640Mon, 29 Jun 2026 08:21:12 +0000Lymphocyte-Platelet and Neutrophil-Platelet Aggregates are Associated with Dysregulated Platelet Inflammatory Pathways in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/lymphocyte-platelet-and-neutrophil-platelet-aggregates-are-associated-with-dysregulated-platelet-inflammatory-pathways-in-psoriasis-r639/BackgroundPsoriasis is a chronic immune-mediated inflammatory disease associated with heightened cardiovascular risk. Platelets are increasingly implicated in this link through their capacity to amplify vascular inflammation and interact with leukocytes. Circulating leukocyte-platelet aggregates are elevated in psoriasis, although the biological significance of these aggregates remains incompletely understood. We investigated whether increased leukocyte-platelet aggregates is associated with alterations in the platelet transcriptomic profile in psoriasis.

Methods

Leukocyte-platelet aggregate levels were compared between psoriasis patients (n = 42) and healthy controls (n = 29). Psoriasis patients were stratified by the cohort median lymphocyte-platelet aggregate (LyPA) or neutrophil-platelet aggregate (NPA) levels into high vs low aggregate groups. Platelet RNA sequencing was then performed to define transcriptomic differences in high-vs low-aggregate psoriasis.

Results

Psoriasis patients (mean age 46; 60% male; 81% Caucasian) had higher LyPA (P = 0.001) and NPA (P = 0.04) compared with healthy controls (mean age 42; 55% male; 69% Caucasian). Platelet RNA sequencing revealed that psoriasis patients with high LyPA or high NPA had downregulation of platelet inflammatory pathways, including interferon, tumor necrosis factor (TNF), IL-8, and IL-6 signaling.

Conclusion

These findings identify inflammatory platelet transcriptomic alterations associated with elevated lymphocyte-platelet and neutrophil-platelet aggregates in psoriasis and motivate further work to define the functional consequences of leukocyte-platelet aggregates in psoriasis.

Weiterlesen

]]>639Mon, 29 Jun 2026 08:21:12 +0000Dual targeting of cutaneous inflammation and vasculopathy via STING-NF-κB blockade underlies the anti-psoriatic efficacy of Yinxie Granules.https://www.psoriasis-news.de/articles.html/1_articles/dual-targeting-of-cutaneous-inflammation-and-vasculopathy-via-sting-nf-%CE%BAb-blockade-underlies-the-anti-psoriatic-efficacy-of-yinxie-granules-r638/Weiterlesen

]]>638Mon, 29 Jun 2026 08:21:12 +0000Musculoskeletal and nail ultrasound findings in children with psoriasis: a case-control study.https://www.psoriasis-news.de/articles.html/1_articles/musculoskeletal-and-nail-ultrasound-findings-in-children-with-psoriasis-a-case-control-study-r632/BackgroundChildren with psoriasis can develop juvenile psoriatic arthritis. Musculoskeletal ultrasound is a helpful imaging modality in the early recognition of joint inflammation. This pilot study aims to describe clinical and subclinical joint and nail abnormalities in children with psoriasis.

Methods

Children with psoriasis and healthy controls underwent ultrasound examination of various joints, entheses, and nails. Using a standard acquisition protocol, images were obtained in both B-mode and PD-mode. Differences between psoriasis and control groups were examined.

Results

Fifteen psoriasis patients who were not on systemic therapy and did not have clinical signs of arthritis and thirteen age- and sex-matched healthy controls were enrolled. While patients with psoriasis demonstrated subclinical synovitis in the finger, knee, and ankle joints more frequently than the control group (p = 0.047), no statistically significant difference was observed in the comparison of each specific joint. PD positivity was detected at the entheses in two patients with psoriasis and at three entheseal sites of two healthy children. Nail ultrasound examination demonstrated significantly thicker nail beds (1.6 vs. 1.4 mm, p < 0.001) and more frequent abnormal nail structure (70% vs. 21.2%, p < 0.001) in the psoriasis group compared to control group while the thickness of the nail plate and nail matrix were similar. Type II nail morphology changes were the most frequently detected type according to the Wortsman classification. Positive PD-mode findings in the nail bed and nail matrix were more common in the control group (both p < 0.001). Among the psoriasis cohort, nails with abnormal exam findings had significantly thicker nail plate (0.4 vs. 0.35 mm, p = 0.003) and nail bed (1.8 vs. 1.6 mm, p = 0.006) measurements compared to nails with normal examination.

Conclusions

Ultrasound is a useful tool for evaluating inflammatory joint and nail findings that may help delineate subclinical joint inflammation in children with psoriasis.

Weiterlesen

]]>632Mon, 25 May 2026 08:01:40 +0000Alkannin ameliorates imiquimod-induced murine psoriasis by targeting MrgprX2-mediated mast cell activation.https://www.psoriasis-news.de/articles.html/1_articles/alkannin-ameliorates-imiquimod-induced-murine-psoriasis-by-targeting-mrgprx2-mediated-mast-cell-activation-r631/Weiterlesen

]]>631Mon, 25 May 2026 08:01:40 +0000Feasibility of Ultrashort Echo Time MR Imaging for the Detection of Subclinical Achilles Enthesitis in Psoriasis and Psoriatic Arthritis.https://www.psoriasis-news.de/articles.html/1_articles/feasibility-of-ultrashort-echo-time-mr-imaging-for-the-detection-of-subclinical-achilles-enthesitis-in-psoriasis-and-psoriatic-arthritis-r630/s) values were significantly elevated in PsO/PsA compared with healthy volunteers. These findings support the feasibility of UTE bicomponent analysis, as a promising tool for evaluating SI and warrant further investigation.

Weiterlesen

]]>630Mon, 25 May 2026 08:01:40 +0000Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.https://www.psoriasis-news.de/articles.html/1_articles/durability-of-response-to-icotrokinra-for-high-impact-site-psoriasis-1-year-iconic-total-findings-r629/Weiterlesen

]]>629Mon, 25 May 2026 08:01:40 +0000Drug-induced psoriasis following sacubitril/valsartan: a case report and literature review.https://www.psoriasis-news.de/articles.html/1_articles/drug-induced-psoriasis-following-sacubitrilvalsartan-a-case-report-and-literature-review-r628/Weiterlesen

]]>628Mon, 25 May 2026 08:01:40 +0000Association of Body Roundness Index, Lipid Accumulation Product, and Triglyceride-Glucose Index With Psoriasis: A Systematic Review of Observational Studies.https://www.psoriasis-news.de/articles.html/1_articles/association-of-body-roundness-index-lipid-accumulation-product-and-triglyceride-glucose-index-with-psoriasis-a-systematic-review-of-observational-studies-r627/Background and aimsLipid dysregulation plays a crucial role in psoriasis pathogenesis and its cardiometabolic comorbidities. Novel anthropometric indices such as Body Roundness Index (BRI), Lipid Accumulation Product (LAP), and Triglyceride-Glucose (TyG) index have been proposed to better reflect underlying metabolic dysfunction and may be associated with psoriasis risk, severity, and related complications. This systematic review evaluates the current evidence on the associations of BRI, LAP, and the TyG index with psoriasis and related clinical outcomes.

Methods

A comprehensive literature search was conducted from inception up to September 2025. Observational studies examining the relationship between BRI, LAP, or TyG index and psoriasis or its clinical outcomes were included. Data synthesis comprised qualitative and descriptive statistical analyses.

Results

Fifteen studies comprising 65,130 participants from diverse countries met the inclusion criteria. Higher LAP was consistently associated with increased psoriasis risk but showed weak or no correlation with disease severity (PASI). All BRI studies, primarily using US National Health and Nutrition Examination Survey data, demonstrated a positive association between BRI and psoriasis risk, with modest predictive ability (AUC 0.56-0.58). TyG index was linked to adverse metabolic and cardiovascular outcomes, fatty liver disease, and all-cause mortality in psoriasis patients, although correlations with PASI were generally non-significant.

Conclusions

BRI, LAP, and TyG index are consistently associated with psoriasis risk and related metabolic and cardiovascular complications, highlighting their potential utility for early risk stratification and holistic management of psoriasis patients. Further prospective studies are warranted to clarify their predictive value for disease severity and long-term outcomes.

Weiterlesen

]]>627Mon, 25 May 2026 08:01:40 +0000Novel post-translational modification learning signature reveals DPP3 promotes progression of psoriasis by enhancing inflammatory activation.https://www.psoriasis-news.de/articles.html/1_articles/novel-post-translational-modification-learning-signature-reveals-dpp3-promotes-progression-of-psoriasis-by-enhancing-inflammatory-activation-r626/Weiterlesen

]]>626Mon, 25 May 2026 08:01:40 +0000Studying the expression levels of LncRNA-MEG3 and miR-147b in the serum of psoriasis patients with and without dyslipidemia.https://www.psoriasis-news.de/articles.html/1_articles/studying-the-expression-levels-of-lncrna-meg3-and-mir-147b-in-the-serum-of-psoriasis-patients-with-and-without-dyslipidemia-r625/Weiterlesen

]]>625Mon, 25 May 2026 08:01:40 +0000Correction: Association between Life's Essential 8 and psoriasis in US adults: a cross-sectional studyhttps://www.psoriasis-news.de/articles.html/1_articles/correction-association-between-lifes-essential-8-and-psoriasis-in-us-adults-a-cross-sectional-study-r624/No abstract supplied.

Weiterlesen

]]>624Mon, 25 May 2026 08:01:40 +0000